Sanofi (0O59) Share Forecast & Price Target

Compare

10 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0O59 Analyst Ratings

Strong Buy

10 Buy

2 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Sanofi

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0O59 Stock 12 Month Forecast

Average Price Target

€107.27

▲(34.93% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Sanofi in the last 3 months. The average price target is €107.27 with a high forecast of €120.00 and a low forecast of €92.00. The average price target represents a 34.93% change from the last price of €79.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"79":"€79","100":"€100","121":"€121","89.5":"€89.5","110.5":"€110.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120.000000144456,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":107.2692994748,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€107.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":92.0000001107496,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€92.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[79,89.5,100,110.5,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.69,87.40615385726585,90.12230771453169,92.83846157179754,95.55461542906338,98.27076928632923,100.98692314359508,103.70307700086093,106.41923085812677,109.1353847153926,111.85153857265846,114.5676924299243,117.28384628719016,{"y":120.000000144456,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.69,86.42686919036923,88.16373838073847,89.90060757110768,91.63747676147692,93.37434595184615,95.11121514221539,96.8480843325846,98.58495352295384,100.32182271332307,102.0586919036923,103.79556109406153,105.53243028443076,{"y":107.2692994748,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.69,85.25230770082689,85.81461540165378,86.37692310248067,86.93923080330757,87.50153850413446,88.06384620496135,88.62615390578824,89.18846160661514,89.75076930744203,90.31307700826892,90.87538470909581,91.4376924099227,{"y":92.0000001107496,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":100.014,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.257,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.535,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.581,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.308,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.177,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.785,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.381,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.827,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.066,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.032,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.69,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€120.00

Average Price Target€107.27

Lowest Price Target€92.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Veda Pharmyne

TR | OpenAI - 4o

€90→€88

Buy

10.69%

Upside

Reiterated

09/06/25

AI Generated ArticleAI Generated Article

Luisa Hector

Berenberg Bank

€118→€110

Buy

38.36%

Upside

Reiterated

09/05/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Sanofi (Other OTC: SNYNF) and Novan (NASDAQ: NOVN)

Florent Cespedes

Bernstein

€119

Buy

49.69%

Upside

Reiterated

09/05/25

Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF) and Novan (NASDAQ: NOVN)

James Quigley

Goldman Sachs

€100→€94

Hold

18.24%

Upside

Reiterated

09/05/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: CareCloud (NASDAQ: CCLD), Novan (NASDAQ: NOVN) and Sanofi (Other OTC: SNYNF)

Matthew Weston

UBS

€115

Buy

44.65%

Upside

Reiterated

09/04/25

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), Sanofi (Other OTC: SNYNF) and Novan (NASDAQ: NOVN)

Richard Vosser

J.P. Morgan

€105

Buy

32.08%

Upside

Reiterated

09/04/25

Sanofi (SNYNF) Receives a Buy from J.P. Morgan

Benjamin Jackson CFA

Jefferies

€120

Buy

50.94%

Upside

Reiterated

09/04/25

Sanofi (SNYNF) Receives a Buy from Jefferies

Sachin Jain

Bank of America Securities

€115

Buy

44.65%

Upside

Reiterated

09/04/25

Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR) and Sanofi (Other OTC: SNYNF)

Simona Pasero

Kepler Capital

€95

Hold

19.50%

Upside

Reiterated

09/04/25

Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF) and Novan (NASDAQ: NOVN)

Emmanuel Papadakis

Deutsche Bank

€90→€110

Buy

38.36%

Upside

Upgraded

09/02/25

Sanofi upgraded to Buy from Hold at Deutsche BankSanofi upgraded to Buy from Hold at Deutsche Bank

Emily Field

Barclays

€115→€105

Buy

32.08%

Upside

Reiterated

08/12/25

Barclays Sticks to Its Buy Rating for Sanofi (SNYNF)

David Risinger

Leerink Partners

€101→€92

Buy

15.72%

Upside

Reiterated

08/04/25

Sanofi Stock: Attractive Valuation and Upcoming Catalysts Support Buy Rating Despite Adjusted Financial Forecasts

Elmar Kraus

DZ BANK AG

―

Buy

―

Reiterated

07/31/25

DZ BANK AG Sticks to Their Buy Rating for Sanofi (SNYNF)

Seamus Fernandez

Guggenheim

€108→€110

Buy

38.36%

Upside

Reiterated

06/02/25

Guggenheim Reaffirms Their Buy Rating on Sanofi (SNYNF)

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

€100

Hold

25.79%

Upside

Initiated

06/02/25

Sanofi (SNYNF) Has a New Rating from Morgan Stanley

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Veda Pharmyne

TR | OpenAI - 4o

€90→€88

Buy

10.69%

Upside

Reiterated

09/06/25

AI Generated ArticleAI Generated Article

Luisa Hector

Berenberg Bank

€118→€110

Buy

38.36%

Upside

Reiterated

09/05/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Sanofi (Other OTC: SNYNF) and Novan (NASDAQ: NOVN)

Florent Cespedes

Bernstein

€119

Buy

49.69%

Upside

Reiterated

09/05/25

Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF) and Novan (NASDAQ: NOVN)

James Quigley

Goldman Sachs

€100→€94

Hold

18.24%

Upside

Reiterated

09/05/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: CareCloud (NASDAQ: CCLD), Novan (NASDAQ: NOVN) and Sanofi (Other OTC: SNYNF)

Matthew Weston

UBS

€115

Buy

44.65%

Upside

Reiterated

09/04/25

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), Sanofi (Other OTC: SNYNF) and Novan (NASDAQ: NOVN)

Richard Vosser

J.P. Morgan

€105

Buy

32.08%

Upside

Reiterated

09/04/25

Sanofi (SNYNF) Receives a Buy from J.P. Morgan

Benjamin Jackson CFA

Jefferies

€120

Buy

50.94%

Upside

Reiterated

09/04/25

Sanofi (SNYNF) Receives a Buy from Jefferies

Sachin Jain

Bank of America Securities

€115

Buy

44.65%

Upside

Reiterated

09/04/25

Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR) and Sanofi (Other OTC: SNYNF)

Simona Pasero

Kepler Capital

€95

Hold

19.50%

Upside

Reiterated

09/04/25

Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF) and Novan (NASDAQ: NOVN)

Emmanuel Papadakis

Deutsche Bank

€90→€110

Buy

38.36%

Upside

Upgraded

09/02/25

Sanofi upgraded to Buy from Hold at Deutsche BankSanofi upgraded to Buy from Hold at Deutsche Bank

Emily Field

Barclays

€115→€105

Buy

32.08%

Upside

Reiterated

08/12/25

Barclays Sticks to Its Buy Rating for Sanofi (SNYNF)

David Risinger

Leerink Partners

€101→€92

Buy

15.72%

Upside

Reiterated

08/04/25

Sanofi Stock: Attractive Valuation and Upcoming Catalysts Support Buy Rating Despite Adjusted Financial Forecasts

Elmar Kraus

DZ BANK AG

―

Buy

―

Reiterated

07/31/25

DZ BANK AG Sticks to Their Buy Rating for Sanofi (SNYNF)

Seamus Fernandez

Guggenheim

€108→€110

Buy

38.36%

Upside

Reiterated

06/02/25

Guggenheim Reaffirms Their Buy Rating on Sanofi (SNYNF)

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

€100

Hold

25.79%

Upside

Initiated

06/02/25

Sanofi (SNYNF) Has a New Rating from Morgan Stanley

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sanofi

1 Month

xxx

Success Rate

28/44 ratings generated profit

Average Return

+0.71%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +0.71% per trade.

3 Months

xxx

Success Rate

12/16 ratings generated profit

Average Return

+1.69%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +1.69% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

22/32 ratings generated profit

Average Return

+4.66%

reiterated a buy rating last month

Copying David Risinger's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +4.66% per trade.

2 Years

xxx

Success Rate

17/23 ratings generated profit

Average Return

+8.83%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 73.91% of your transactions generating a profit, with an average return of +8.83% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0O59 Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0O59 has received 32 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. 0O59 average Analyst price target in the past 3 months is 107.27.

Each month's total comprises the sum of three months' worth of ratings.

0O59 Financial Forecast

0O59 Earnings Forecast

Next quarter’s earnings estimate for 0O59 is €2.84 with a range of €2.69 to €3.07. The previous quarter’s EPS was €1.59. 0O59 beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year 0O59 has Outperformed its overall industry.

0O59 Sales Forecast

Next quarter’s sales forecast for 0O59 is €13.03B with a range of €12.38B to €13.59B. The previous quarter’s sales results were €19.89B. 0O59 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.33% of the time in the same period. In the last calendar year 0O59 has Outperformed its overall industry.

0O59 Stock Forecast FAQ

What is GB:0O59’s average 12-month price target, according to analysts?

Based on analyst ratings, Sanofi’s 12-month average price target is 107.27.

What is GB:0O59’s upside potential, based on the analysts’ average price target?

Sanofi has 34.93% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Sanofi a Buy, Sell or Hold?

Sanofi has a consensus rating of Strong Buy, which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.

What is Sanofi’s share price target?

The average share price target for Sanofi is 107.27. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €120.00 ,and the lowest forecast is €92.00. The average share price target represents 34.93% Increase from the current price of €79.5.

What do analysts say about Sanofi?

Sanofi’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of Sanofi?

To buy shares of GB:0O59, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Sanofi (0O59) Share Forecast & Price Target

0O59 Analyst Ratings

0O59 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sanofi

0O59 Analyst Recommendation Trends

0O59 Financial Forecast

0O59 Earnings Forecast

0O59 Sales Forecast

0O59 Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts